CoChat

Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man

Open access
Rosen, S G, Clutter, W E, Berk, M A, Shah, S D, Cryer, P E · 1984 · Journal of Clinical Investigation

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 10 of the 73 sources its claims cite were checked for support.

Abstract

We hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration, and prevent hypoglycemia when glucagon secretion is deficient. Accordingly, we assessed the impact of glucagon deficiency, produced by infusion of somatostatin with insulin, without and with pharmacologic alpha- and beta-adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects. During somatostatin with insulin alone mean glucose production fell from 1.5 +/- 0.05 to 0.7 +/- 0.2 mg/kg per min and mean plasma glucose declined from 93 +/- 3 to 67 +/- 4 mg/dl over 1 h; glucose production then increased to base-line rates and plasma glucose plateaued at 64-67 mg/dl over 2 h. This plateau was associated with, and is best attributed to, an eightfold increase in mean plasma epinephrine. It did not occur when adrenergic blockade was added; glucose production remained low and mean plasma glucose declined progressively to a hypoglycemic level of 45 +/- 4 mg/dl, significantly (P less than 0.001) lower than the final value during somatostatin with insulin alone. These data provide further support for the concept that maintenance of the postabsorptive plasma glucose concentration is a function of insulin and glucagon, not of insulin alone, and that adrenergic mechanisms do not normally play a critical role. They indicate, however, that an endogenous adrenergic agonist, likely adrenomedullary epinephrine, compensates for deficient glucagon secretion and prevents hypoglycemia in the postabsorptive state in humans. Thus, postabsorptive hypoglycemia occurs when both glucagon and epinephrine are deficient, but not when either glucagon or epinephrine alone is deficient, and insulin is present.

Overview

CoChat Summary

TL;DR

In normal humans, glucagon deficiency produced by somatostatin plus insulin caused an initial fall in glucose production and plasma glucose, followed by a rebound in glucose production and a glucose plateau at 64–67 mg/dl. Adding α- and β-adrenergic blockade prevented the plateau and led to progressive hypoglycemia (45±4 mg/dl), indicating that epinephrine compensates for deficient glucagon secretion to support postabsorptive glucose and prevent hypoglycemia.

Key findings

  • During somatostatin with insulin alone, mean glucose production fell from 1.5±0.05 to 0.7±0.2 mg/kg per min at 50 min, and mean plasma glucose declined from 93±3 to 67±4 mg/dl at 60 min, then plateaued at 64–67 mg/dl; the 180-min value was 64±4 mg/dl, not significantly different from 60 min.
  • With added propranolol plus phentolamine, the initial glucose fall was similar, but plasma glucose declined progressively to 45±4 mg/dl at 180 min, significantly lower than 64±4 mg/dl during somatostatin with insulin alone (P < 0.001); glucose production remained below baseline and was significantly lower by 80 min (P < 0.05), with no changes in glucose utilization.
  • Plasma epinephrine rose more than eightfold, from 18±4 to 153±33 pg/ml at 180 min (P < 0.01), during somatostatin with insulin alone; norepinephrine rose from 156±11 to 271±29 pg/ml (P < 0.01).
  • Blood lactate rose from 770±84 to 1,095±136 μmol/liter at 130 min (P < 0.02) during somatostatin with insulin alone, and this rise did not occur with adrenergic blockade; blood glycerol also fell progressively with blockade, supporting biologically active epinephrine release.

Methods

  • 10 normal human subjects (six women, four men), ages 18–33 yr and within 15% of ideal body weight, were studied after an overnight fast in the supine position.
  • A primed continuous [3-3H]glucose infusion was used; somatostatin (250 μg/h) plus regular porcine insulin (200 μU/kg per min) was infused from 0 through 180 min, with or without propranolol (0.08 mg/min after 5.0 mg over 2 min) and phentolamine (0.5 mg/min after 5.0 mg over 2 min) from −30 through 180 min; study sequence was randomized.
  • Plasma glucose, glucose kinetics, insulin, C-peptide, glucagon, growth hormone, cortisol, epinephrine, norepinephrine, and blood alanine, lactate, glycerol, and β-hydroxybutyrate were measured; data are mean±SE and were analyzed with a paired t test.

Limitations

  • The paper states that the insulin dose was a compromise: it could not produce isolated glucagon deficiency with portal insulin at baseline levels, and the protocol produced mild peripheral venous hyperinsulinemia (~20–60% above baseline) with estimated portal venous insulin approximately two-thirds of baseline.
  • The paper notes that measured glucagon decrements were small because the antiserum cross-reacts with species other than 3,500-dalton glucagon, although biologically active glucagon was likely suppressed substantially; it also states that the data do not exclude an additional effect of epinephrine on glucose utilization during glucagon deficiency.
  • Evident from the text: the study is small (10 normal subjects), acute (3 h), uses pharmacologic nonselective adrenergic blockade, and does not directly measure portal insulin or glucagon concentrations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci111226

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 Valid · 0 Not valid · 16 Not checked · 38 Own results and interpretations

31 more claims

Create a free account to see all 60 claims and to verify the 13 references still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 42 references

Cited by

See all 41

Metadata

Authors
Rosen, S. G., Clutter, W. E., Berk, M. A., Shah, S. D., & Cryer, P. E.
Affiliations
Washington University in St. Louis (US)
Venue
Journal of Clinical Investigation
Published
1984-02-01
Volume
73
Issue
2
Pages
405-411
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1984337511
Cited by
41
References
44
Citations by year
2024: 1 · 2020: 1 · 2016: 1
FWCI
5.71
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
epinephrine, glucagon deficiency, hypoglycemia, adrenergic mechanisms, glucose kinetics, glucose production, somatostatin, insulin, alpha-adrenergic blockade, beta-adrenergic blockade
MeSH terms
Absorption, Adolescent, Adult, Blood Glucose, Epinephrine, Female, Glucagon, Humans, Insulin, Kinetics, Male, Norepinephrine, Phentolamine, Propranolol, Somatostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. https://app.cochat.ai/papers/10.1172/jci111226
The paper
Rosen, S. G., Clutter, W. E., Berk, M. A., Shah, S. D., & Cryer, P. E. (1984). Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. Journal of Clinical Investigation. https://doi.org/10.1172/jci111226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.